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ABSTRACT
Objectives: Neutropenia and its complications, including
febrile neutropenia (FN), are a common side effect of cancer
chemotherapy. Results of clinical trials showed that prophy-
lactic use of granulocyte colony-stimulating factors (G-CSF)
is effective in preventing FN. In this study, the cost effective-
ness (measured as cost per quality-adjusted time [days]) of
three treatment alternatives were evaluated: no G-CSF,
ﬁlgrastim administered daily for 7–12 days after chemo-
therapy, and a pegylated form of G-CSF pegﬁlgrastim,
administered once per cycle.
Methods: A cost-utility model based on standard clinical
practice of treating FN with immediate hospitalization or
with ambulatory treatment, from a societal perspective was
developed. Direct medical cost estimates for hospitalization
were derived from claims data reported by 115 US aca-
demic medical centers. Indirect medical costs, productivity
costs, probabilities, and utilities are based on published lit-
erature. Results were subjected to sensitivity analyses and
95% conﬁdence intervals are based on a Monte Carlo
simulation.
Results: Mean estimated costs/day of hospitalization were
$1984 (SD $1040, N = 24,687) for surviving patients and
$3139 (SD $2014, N = 1437) for dying patients. Under base-
line conditions, pegﬁlgrastim dominated both ﬁlgrastim and
no G-CSF, with expected costs and effectiveness of $4203 and
12.361 quality adjusted life-days (QALDs) for no G-CSF,
$3058 and 12.967 QALDs for pegﬁlgrastim, and $5264 and
12.698 QALDs for ﬁlgrastim.
Conclusions: This cost-utility analysis provides strong evi-
dence that pegﬁlgrastim is not only cost-effective but also
cost-saving in most common clinical and economic settings.
There appear to be both clinical and economic beneﬁts from
prophylactic administration of pegﬁlgrastim.
Keywords: cancer, cost analysis, decision models, febrile
neutropenia, granulocyte colony-stimulating factors,
neutropenia.
Introduction
Neutropenia is a common chemotherapy-related com-
plication. Neutropenia is deﬁned as a below normal
count of neutrophils (white blood cells), which are
particularly important in ﬁghting and preventing infec-
tion. Febrile neutropenia (FN), deﬁned as the presence
of both neutropenia and fever, routinely prompts imme-
diate hospitalization for evaluation and administration
of empirical broad-spectrum antibiotics [1] and may
subsequently result in chemotherapy dose delays or
reductions [2]. It is estimated that in the United States,
more than 60,000 neutropenia-related hospitalizations
occur each year [3]. The costs associated with those
hospitalizations add signiﬁcantly to the direct medical
costs of cancer treatment and pose a great ﬁnancial
burden in the overall care of cancer patients [4].
Considerable attention has been given in recent
years to identifying FN patients at low risk of com-
plications who may be candidates for outpatient
treatment with antibiotics [5]. Although replacing hos-
pitalization and intravenous (IV) antibiotic treatment
with outpatient oral antibiotics holds promise for
savings, a formal cost analysis of outpatient treatment
demonstrated only limited economic effect on the
overall cost of cancer treatment as low-risk patients
account for a small proportion of the overall costs of
cancer patient care for FN [6].
Randomized controlled trials (RCTs) have de-
monstrated that prophylactic granulocyte colony-
stimulating factors (G-CSF; ﬁlgrastim) initiated after
myelosuppressive chemotherapy and administered
daily until neutrophil recovery is effective in reducing
the incidence of FN by as much as 50% [7,8]. Patients
treated with a G-CSF have shorter lengths of hospital-
ization (LOS) and shorter time to neutrophil recovery
than control subjects [9]. Recently updated guidelines
of the American Society of Clinical Oncology (ASCO)
and the European Organization for Research and
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Treatment of Cancer (EORTC) recommend primary
(ﬁrst cycle) prophylactic G-CSF administration for
chemotherapy regimens associated with an FN inci-
dence rate of 20% or greater, or when special circum-
stances exist, such as history of recurrent FN or more
advanced cancer [10–12].
A new, long-acting pegylated form of G-CSF, peg-
ﬁlgrastim (Neulasta; Amgen Inc., Thousand Oaks,
CA) administered once per chemotherapy cycle, has
been shown in recent RCTs to be at least as effective
and safe as ﬁlgrastim [13,14], demonstrating a relative
risk reduction (RRR) for FN greater than 90% [15].
Because of its convenient administration to both the
patient and medical staff and potentially increased
effectiveness, pegﬁlgrastim often displaces ﬁlgrastim in
the United States whenever it is being reimbursed by
payers [16]. Many patients receiving conventional
systemic chemotherapy are not receiving primary
prophylaxis with G-CSF [2,17], suggesting that
many physicians still consider “watchful waiting”
a valid treatment option during the ﬁrst cycle of
chemotherapy.
Although the economic impact of ﬁlgrastim has
been well studied, indicating that primary prophylaxis
in patients receiving chemotherapy can be cost-
effective compared with “no G-CSF” (attributed
mainly to a decreased risk of FN) [18,19], and despite
considerable clinical interest and wide-scale use of peg-
ﬁlgrastim, a thorough economic evaluation of peg-
ﬁlgrastim has not been previously reported. The
objective of this analysis is to evaluate the economic
impact of pegﬁlgrastim compared with ﬁlgrastim and
no G-CSF when administered prophylactically during
the ﬁrst cycle of chemotherapy.
Methods
Decision Analysis
A cost-utility (CU) model was created to compare the
economic impact of three treatment alternatives:
primary prophylactic use of pegﬁlgrastim, primary
prophylactic use of ﬁlgrastim, and no prophylactic
G-CSF (Fig. 1). This model was premised on common
clinical practice, in which patients receiving chemo-
therapy are at risk for developing FN. Patients experi-
encing FN are then managed either as inpatients or as
outpatients based on their risk of serious complica-
tions or death. An outpatient treatment includes the
administration of IV antibiotics and may be fol-
lowed by hospitalization if the patient’s condition
deteriorates.
The modeled population consists of patients
between the ages of 18 and 65 years old, hospitalized
between 1995 and 2003 for a solid tumor cancer
as identiﬁed by the International Classiﬁcation of
Disease, Ninth version, Clinical Modiﬁcation (ICD-9-
CM) codes 140.00 to 199.00, and also with a diagno-
sis of neutropenia (agranulocytosis), ICD-9-CM code
288.00. Costs and LOS were estimated for surviving
and dying patients separately.
The analysis was performed from the societal
perspective, incorporating direct as well as indirect
medical costs, productivity costs, and travel costs
(Table 1). Costs are measured in US dollars, adjusted
to 2005 using the Consumer Price Index—Urban for
medical care [29]. Effectiveness is measured in quality-
adjusted life-days (QALDs). The time horizon is the
ﬁrst cycle of chemotherapy deﬁned as 21 days, when
most patients receive full-dose chemotherapy, often
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Figure 1 Clinical decision model for studying
the effect of prophylactic use of pegﬁlgrastim or
ﬁlgrastim on the expected costs of cancer treat-
ment per patient in the ﬁrst cycle, showing two
standard clinical strategies. FN, febrile neutro-
penia; G-CSF, granulocyte colony-stimulating
factors.
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without G-CSF prophylaxis [30] and because the
occurrence of FN during the ﬁrst cycle of chemo-
therapy is shown to be a good predictor of neutropenic
events in subsequent cycles [31]. The model was con-
structed using decision analysis computer software
TreeAge Pro2005 (TreeAge Software Inc., William-
stown, MA).
Probabilities
Probabilities including incidence of FN, hospitaliza-
tion for FN, mortality, and RRR of ﬁlgrastim and
pegﬁlgrastim were based on the published literature
[4,9,15,21]. Several studies are available describing
the use of IV antibiotics in the outpatient setting in
terms of both efﬁcacy and duration of treatment
[5,20,22,32]. Based on those studies, our base case
analysis assumes no FN-related deaths occur in outpa-
tient settings, because these patients are highly selected
low-risk patients. Probability of hospitalization among
those initially treated as outpatients and who subse-
quently developed more severe symptoms requiring
hospitalization is based on Talcott [20]. The model
assumes that if such hospitalizations are needed, they
occur half way through outpatient treatment. Baseline
probabilities, their ranges tested in sensitivity analyses,
and references are presented in Table 1.
Cost Estimates
The University HealthSystem Consortium (UHC) is a
database incorporating information from 115 aca-
demic medical centers and 149 of their afﬁliated
hospitals, representing approximately 90% of US non-
proﬁt academic medical centers. The data set includes
clinical as well as administrative information designed
primarily to provide participating hospitals with the
needed information to improve their performance.
Average hospitalization costs were estimated for each
participating institution within the UHC from detailed
hospital charges collected at the revenue code level and
mapped into individual departments. Departmental
Table 1 Summary of parameters used in decision analysis: numeric baseline values, parameter range used in sensitivity analyses,
distribution type and parameters, and references
Model parameters Baseline value
Range tested in
sensitivity analysis
Distribution type
and parameters* References
Probabilities
Incidence of FN 0.2 0.05–0.4 Point estimate [15]
Hospitalization for FN 0.82 0.5–1 Beta, SD 0.04 [15]
Hospitalization for FN following outpatient treatment 0.16 0.1–0.5 Beta, SD 0.06 [20]
FN-related death, while outpatient treatment for FN 0 0–1 Point estimate [15,20]
FN-related death, while hospitalized for FN 0.08 0.01–0.2 Beta, SD 0.03 [4]
RRR of FN associated with pegﬁlgrastim 0.9 0.5–1 Point estimate [15,21]
RRR of FN associated with ﬁlgrastim 0.39 0.28–0.48 Point estimate [21]
FN-related hospitalization 0.88 0.7–1 Beta, SD 0.03 [15]
Reduction in LOS associated with G-CSF 0.2 0–0.5 Point estimate [9]
Time [unit of measurement]
Hospital LOS for surviving patients (days) 9 1–30 Point estimate UHC
Hospital LOS for dying patients (days) 15 1–30 Point estimate UHC
FN as outpatient (days) 5 4–6 Uniform, SD 0.57 [22]
Number of ﬁlgrastim injection 8 7–12 Point estimate [19]
Patient’s time for IV antibiotic injection, outpatient (hours) 3.26 0.8–7.5 Gamma, SD 0.98 [23]
Patient’s time for ﬁlgrastim injection, outpatient (hours) 2.32 0.45–4.3 Gamma, SD 0.87 [23]
Patient’s time for pegﬁlgrastim injection (hours) 2.36 1.45–11.2 Gamma, SD 1.45 [23]
Costs (US$, 2005)
IV antibiotics per injection† 36 15–100 Point estimate [24]
Hospitalization per day for surviving patients 1971 1000–5000 Lognormal, SD 937.8 UHC
Hospitalization per day for dying patients 3128 1000–5000 Lognormal, SD 1977.8 UHC
Filgrastim, per injection† 282 207.5–362.6 Point estimate [24]
Pegﬁlgrastim per injection† 2603 1500–4000 Point estimate [24]
Physician cost/day 200 0–500 Point estimate MedStat
Cost of medical staff per episode of outpatient IV antibiotics injection 91 39–162 Lognormal, SD 46.3 [22]
Cost of medical staff per episode of outpatient ﬁlgrastim injection 63.4 12–147 Lognormal, SD 31.73 [22]
Cost of medical staff per episode of outpatient pegﬁlgrastim injection 62.33 12–122 Lognormal, SD 33.53 [22]
Travel per outpatient visit/hospitalization 14 10–20 Point estimate [25]
Patient’s average hourly wage 18 12–20 Lognormal, SD 15.7 [26]
Utilities
Cancer with chemotherapy treatment 0.62 0.4–0.84 Point estimate [27]
Infection without hospitalization 0.48 0–1 Point estimate [27]
FN with hospitalization 0.24 0.12–0.36 Point estimate [27]
Difference in utility attributed to G-CSF‡ 0 (-0.2)-0.2 Point estimate [28]
*Mean is as speciﬁed in baseline value, unless otherwise speciﬁed.
†Cost presented incorporates 15% discount, reﬂecting average institutional discount below average wholesale price.
‡Range is based on assumption.
The information contained in this article was based in part on the Clinical Data Products Database maintained by the University HealthSystem Consortium (UHC).
FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factors; IV, intravenous; IRM, infection-related mortality; LOS, length of stay; RRR, relative risk reduction.
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costs were estimated from reported charges by multi-
plying the department charge by trimmed mean cost-
to-charge ratios. Total hospitalization costs per patient
were computed by summing individual cost center
estimates.
Physician costs per day were based on validated
patient-level data from commercial, Medicare and
Medicaid claims (MarketScan: http://www.medstat.
com) provided on some 7 million covered lives by large
employers, nationwide plans including Blue Cross/Blue
Shield, third-party administrators, and patients with
primary coverage or Medicare Supplemental coverage
through privately insured fee-for-service, point of
service, or capitated health plans. This data set has been
validated and used in both cancer and noncancer
studies [33,34]. Outpatient medical staff costs were
based on a study carried out by Fortner et al. [22], in
which the researchers measured time and costs for
various human resources, including both medical and
nonmedical services necessary to manage chemo-
therapy, chemotherapy-induced neutropenia, and
administration of IV antibiotics in 20 community
oncology practices in the United States. Prices of peg-
ﬁlgrastim (6 mg), ﬁlgrastim (300 mg and 480 mg), and
IV antibiotics (ceftazidime, 2 g) were obtained from the
2005 Drug Topics Red Book [24], discounted 15% of
their average wholesale price to reﬂect institutional
contract prices. At baseline, the model assumes that in
outpatient settings, pegﬁlgrastim was administered
once per cycle, ﬁlgrastim was administered in clinic for
eight consecutive days, and IV antibiotics were admin-
istered once a day, for 5 days.
Patient time spent on treatment was valued using
measures of patients’ time spent on clinic visits, includ-
ing their travel time to and from the clinic [23]. Each
day of hospitalization was assumed to cause the loss of
8 hours of paid work. Average hourly earnings are
based on data collected by the US Department of
Labor, Bureau of Labor Statistics, 2004 for all occu-
pations [26]. The cost of round-trip travel was valued
at $14 per outpatient visit or hospitalization, based
on the standard mileage rate for calculating tax-
deductible travel [25] and an assumption that each
patient had to travel 35 miles per visit. We did not
account for out-of-pocket expenses. Baseline costs and
their ranges tested in sensitivity analyses are presented
in Table 1.
Health Outcome
QALDs were estimated from the duration in a given
health state, adjusted by the appropriate preference-
based quality weight (utilities) associated with the
health state. Utilities for the three health states repre-
sented in the model—stable disease, FN with hospital-
ization, and FN without hospitalization—were derived
from a study where 180 nurses served as proxies in
evaluating cancer patients’ preferences, using the stan-
dard gamble method. Health states were deﬁned
without speciﬁcation of chemotherapy regimens or
cancer type and hence could be applied to our modeled
population [27]. Limited data from available trials
exploring the impact of G-CSF on patients’ quality of
life or survival have failed to demonstrate a signiﬁcant
difference between the two strategies [28,35]. There-
fore, it is assumed at baseline that health state utilities
do not vary among the three treatment arms, and any
variation in QALDs will result from differences in the
duration spent in each state. Utilities were varied in a
sensitivity analysis to compare the impact on the dif-
ferent treatment strategies. Utilities and time spent in
each health state, as well as their ranges tested in
sensitivity analysis are presented in Table 1.
Sensitivity Analyses
One-way sensitivity analysis was performed for each
parameter in the model over a clinically or economi-
cally plausible range of values (Table 1). Because esti-
mates of RRR for ﬁlgrastim and pegﬁlgrastim are
based on different RCTs, we tested the assumption of
no difference in RRR between the two treatments with
a combined RRR value of 0.53 compared with no
G-CSF, based on a meta-analysis combining all studies
[21].
To provide a more comprehensive examination of
the uncertainty in the model parameters and assump-
tions and to establish an empirical distribution of the
results of the study, a probabilistic sensitivity analysis
was conducted using a second-order Monte Carlo
simulation. The simulation was conducted based on
5000 iterations providing 95% conﬁdence intervals for
the mean incremental cost-effectiveness ratio (ICER),
by sampling values from all parameter distributions.
Estimates of mean costs approximated a log-normal
distribution, while probabilities and incidences were
assumed to follow a beta distribution and estimates of
mean patient time were assumed to follow a gamma
distribution [36].
Results
Costs and Length of Stay Analysis
Cost data were available on 24,687 patients surviving
hospitalization with FN and 1437 patients dying
during the course of FN hospitalization. The mean
(SD) and median estimated hospitalization costs per
day were $1984 ($1040) and $1717, respectively, for
surviving patients and $3139 ($2014) and $2545 for
dying patients. Distributions for both groups followed
the log-normal distribution. Average hospitalization
LOS was 9 days (range 1–30 days) in surviving
patients and 15 days (range 1–30 days) for patients
who died.
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Baseline Analysis
Under baseline conditions, pegﬁlgrastim dominated
both no G-CSF and ﬁlgrastim because it was the least
costly and most effective (Table 2). Mean costs
(savings) associated with pegﬁlgrastim were ($1128)
compared with no G-CSF and ($2195) compared with
ﬁlgrastim. Mean difference in effectiveness was 0.606
QALD and 0.269 QALD, respectively.
Sensitivity Analyses
Univariate sensitivity analyses were conducted for all
model parameters over the ranges of values speciﬁed in
Table 1. Results of sensitivity analyses for RRR of
ﬁlgrastim, cost of IV antibiotics, LOS for dying
patients, cost/day of dying patients, and cost of IV
antibiotics were robust to value changes.
The effect of varying the probability of FN demon-
strates that pegﬁlgrastim dominates both alternatives
at values greater than 14%; under lower values it will
be more costly and more effective than no G-CSF (with
ICER of $11,616/QALD at the lowest probability
value of 5%) and continue to dominate ﬁlgrastim.
Similarly, varying RRR of pegﬁlgrastim demonstrates a
cost-neutral threshold at an RRR = 0.56; at higher
values, pegﬁlgrastim dominates both alternatives, and
at lower values it dominates ﬁlgrastim but is more
costly and more effective than no G-CSF (with ICER of
$534/QALD at lowest RRR value of 0.5). Varying the
cost of pegﬁlgrastim shows that only for prices higher
than $3700 prophylactic pegﬁlgrastim strategy results
in a net increase in cost compared with no G-CSF
(ICER of $444/QALD when the cost is $4000).
Thresholds for LOS and cost/day of surviving patients
under which pegﬁlgrastim dominates both arms are
N = 6 and cost/day = $1100 (with ICER of $11,295/
QALD for N = 1 and ICER of $315/QALD for cost/
day = $1000), respectively. Varying the difference in
utilities between G-CSF arms and no G-CSF shows
that even if G-CSFs are 4% less effective than no
G-CSF (i.e., G-CSF has lower utility values), peg-
ﬁlgrastim still dominates. If G-CSF results in utility
decreases greater than 4%, no G-CSF becomes the
most effective strategy.
Testing the assumption of equal RRR of both
ﬁlgrastim and pegﬁlgrastim at a value of 0.53 showed
that pegﬁlgrastim still dominated its alternatives. It
was the least costly with incremental cost (savings)
of ($23) and ($487) compared with no G-CSF and
ﬁlgrastim, respectively. Pegﬁlgrastim was equally effec-
tive as ﬁlgrastim but more effective than no G-CSF,
creating additional 0.43 QALDs.
Results from Monte Carlo simulation show mean
(SD) expected costs and effectiveness for no G-CSF
arm to be $4203 ($1462) and 12.361 QALDs (0.022),
for the pegﬁlgrastim arm $3058 ($123) and 12.967
QALDs (0.001), and for the ﬁlgrastim arm $5264
($772) and 12.698 QALDs (0.01). The lower SD dem-
onstrated in the cost of the pegﬁlgrastim arm is attrib-
uted mainly to the reduction in the incidence of FN,
thus compressing the high-risk values (and their
related expected costs) toward the goal of no FN risk.
Figure 2 shows two scatter plots of ICERs: the scatter
plot of ICERs of pegﬁlgrastim compared with no
G-CSF demonstrates that no G-CSF is less effective in
all iterations but is more costly in about 80% of itera-
tions, and the scatter plot of ICERs of pegﬁlgrastim
Table 2 Incremental cost effectiveness analysis comparing treatment alternatives
Intervention
Cost
($US, 2005)
Effectiveness
(QALDs)
Incremental
cost (DC)
Incremental
effectiveness
(DE)
Incremental cost-effectiveness
ratio (DC/DE)
Pegﬁlgrastim 3057 12.967 — —
No G-CSF* 4185 12.362 1128 -0.606 Dominated
Filgrastim* 5252 12.698 2195 -0.269 Dominated
*Compared with pegﬁlgrastim.
G-CSF, granulocyte colony-stimulating factor; QALD, quality-adjusted life days.
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Figure 2 Results of Monte Carlo simulation
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effectivneess ratio of no G-CSF versus peg-
ﬁlgrastim and ﬁlgrastim versus pegﬁlgrastim.
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compared with ﬁlgrastim demonstrates that the ICERs
fall within the upper left quadrant of the cost-
effectiveness plane at all iterations.
Discussion
In the study reported here, a decision analytic model
was used to conduct a CU analysis of primary prophy-
laxis pegﬁlgrastim compared with primary pro-
phylaxis ﬁlgrastim and to no prophylactic G-CSF in
cancer patients receiving systemic chemotherapy.
Two common clinical practices for treating FN were
considered: immediate hospitalization or ambulatory
treatment followed by hospitalization, if needed. The
results of the model suggest that despite the added cost
of pegﬁlgrastim, the overall cost of care is reduced
when pegﬁlgrastim is used prophylactically with che-
motherapy regimens associated with approximately a
16% or greater risk of FN. Monte Carlo simulation
suggests that prophylactic pegﬁlgrastim is associated
with an actual cost savings in approximately three-
quaters of patients receiving prophylactic pegﬁlgrastim
compared with patients without prophylactic G-CSF,
and with increases in QALDs whenever G-CSFs are
used. These cost savings and increased effectiveness are
primarily due to the reduction in hospitalization for
FN along with a reduction in severity of FN, allowing
for shorter hospitalization. The results reported here,
in addition to the compelling evidence for clinical
beneﬁt from several RCTs, are consistent with current
recommendations of ASCO guidelines to use prophy-
lactic pegﬁlgrastim when the risk of FN is 20% or
greater.
In the model presented here, the two comparison
groups shown in Figure 2 fall within two quadrants of
the cost-effectiveness plane; no G-CSF versus peg-
ﬁlgrastim falls within the upper left and lower left
quadrants, indicating that about 80% of the joint
density is associated with cost savings for pegﬁlgrastim
with all of the contrasts yielding gains in QALDs for
pegﬁlgrastim. Filgrastim versus pegﬁlgrastim falls only
within the upper left quadrant, indicating that peg-
ﬁlgrastim is always less expensive and more effective
than ﬁlgrastim. These results are relatively unique
because in the current cost-effectiveness literature, only
a small fraction of reported interventions are actually
cost-saving [37]. Moreover, even in the 20% of itera-
tions where pegﬁlgrastim was more expensive, it may
still be cost-effective. As with other interventions, if
they indeed provide improved health, it may be rea-
sonable to have net increases in cost associated with
them.
The analysis presented here is focused on the ﬁrst
cycle of chemotherapy for two reasons: ﬁrst, it is the
ﬁrst cycle when most patients receive full-dose chemo-
therapy generally without growth factor prophylaxis.
As a result, the ﬁrst cycle of chemotherapy has been
consistently associated with a greater risk of FN than
subsequent cycles. Parameter estimates change little
over multiple cycles, unless there is a change in deliv-
ered dose intensity or the addition of G-CSF. There-
fore, in settings where maintaining chemotherapy dose
intensity is thought to be important for disease control,
subsequent cycles of chemotherapy administered at
full-dose intensity will be accompanied by the same or
greater risk of FN unless growth factors are adminis-
tered prophylactically. Second, the majority of patients
experiencing neutropenia or its complications in the
ﬁrst cycle also experience dose reductions, treatment
delays, or the addition of G-CSF on subsequent cycles
and, as a result, FN episodes in successive cycles may
be related.
Recent studies have demonstrated that prophylactic
antibiotics may also reduce the risk of FN among
patients receiving chemotherapy, especially among
those with hematologic malignancies [38,39]. Never-
theless, prophylactic antibiotics do not address the
underlying neutropenia and are not currently recom-
mended by any medical professional society because of
evidence that such treatment may increase the risk of
developing antibiotic resistance [1,10]. In addition, a
recent randomized phase III trial investigating the role
of adding primary prophylaxis G-CSF to antibiotic
prophylaxis in small-cell lung cancer demonstrated
that the incidence of FN was further reduced during
the ﬁrst cycle with G-CSF (24% vs. 10%, P = 0.01),
and as noted previously, the risk of FN was the highest
during the ﬁrst cycle and decreased substantially in
subsequent cycles [32]. These ﬁndings emphasize the
importance of the ﬁrst cycle of chemotherapy and the
role of preventing FN during this cycle as discussed
above.
The model presented here has several limitations.
The baseline model combines estimates of FN, RRR of
ﬁlgrastim, andRRRof pegﬁlgrastim from clinical trials.
Those studies differ in their chemotherapy regimen,
creating different baseline risk levels of FN. Because the
association between baseline risk of FN and clinical
effectiveness of G-CSF is not fully determined, the
baseline results may vary. Using a RRR of ﬁlgrastim,
which is a weighted summary across different chemo-
therapy regimens as calculated in a meta-analysis,
should reduce the potential variability. The estimates of
RRR for pegﬁlgrastim are also based on the meta-
analysis but include only one published RCT [15,21].
This multicenter, multinational study, however, repre-
sents the largest RCT of a myeloid growth factor
reported to date. Moreover, as the sensitivity analyses
show, even when varying the values mentioned above
across their plausible clinical values, or when equating
their clinical effectiveness (i.e., RRR), pegﬁlgrastim
remains dominant under most values.
Although it is estimated that more than half of
cancer patients in the United States are older than
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65 years, the modeled population is deﬁned as patients
between 18 and 65 years of age, which limits the gen-
eralizability of the model. The fact that the study
population was limited to the 65-years-and-less age
group permitted a better deﬁnition of the costs incor-
porated into the model (e.g., productivity cost, a com-
ponent of which would be problematic to estimate
when dealing with elderly population). In addition,
comorbidities among different age groups may vary,
implicating great variability in length and costs of hos-
pitalization. The meta-analysis of RCTs of prophylac-
tic G-CSF used to estimate RRRs incorporates data
from 17 RCTs in adult cancer patients, including six
that excluded elderly patients more than 65 years of
age, four that included only patients older than the age
of 60, and the rest, which allowed patients of all ages.
No signiﬁcant difference in clinical efﬁcacy among dif-
ferent age groups was found. By specifying the deﬁned
study population considered here, the accuracy of
“real-world” costs based on our model should be
increased.
Another limitation of the model is the derivation of
hospitalization cost per day from an administrative
data set of hospitalization charges of academic hospi-
tals. Although the charges are adjusted based on a
department-speciﬁc cost-to-charge ratio to appropri-
ately address the societal perspective our analysis
takes, the estimates may still be somewhat higher than
when treating FN in a nonacademic hospital.
Further analysis that takes into consideration a
longer time horizon and the potential long-term effects
of pegﬁlgrastim and ﬁlgrastim on chemotherapy dose
reductions or delays and survival should be under-
taken. The model presented here compares only two
treatment alternatives—prophylactic G-CSF (either
ﬁlgrastim or pegﬁlgrastim) versus no G-CSF at
all—and does not consider the cases where patients are
given G-CSF only secondarily after already presenting
to the hospital with FN. Our estimates of FN risk and
hospitalization while using pegﬁlgrastim or ﬁlgrastim
are based largely on evidence from RCTs. These trials
are designed primarily to test the safety and efﬁcacy
of a treatment, and are usually restricted to highly
selected patients, leading to a potential bias when
applying results to the general disease population.
Nevertheless, estimates of infection-related mortality
in the control arm of the RCTs were similar to those
reported in cohort or observational studies of cancer
patients experiencing FN [4].
This analysis provides evidence that pegﬁlgrastim is
not only cost-effective but, in most cases, also cost-
saving across a wide range of estimates of clinical and
economic values. Therefore, in addition to compelling
evidence for considerable clinical beneﬁt with moder-
ately myelosuppressive regimens, primary prophylaxis
with pegﬁlgrastim reduces costs in settings where
maintaining treatment dose intensity is considered
important to providing patients with optimal long-
term disease control or cure.
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